Eli Lilly, Novo Nordisk and Sanofi CEOs to testify before Senate on lowering insulin prices

Eli Lilly, Novo Nordisk and Sanofi control 90% of the insulin market in the U.S, where a quarter of all health-care spending is on people with diabetes.

from Health and Science https://ift.tt/sHiFdrt
https://ift.tt/G0lyTkh
https://ift.tt/A8kwXp0